Adults with primary primary appendiceal adenocarcinoma face a higher risk of developing a second primary cancer, including ...

SAN DIEGO - Inhibrx Biosciences, Inc. (NASDAQ: INBX), a clinical-stage biopharmaceutical company valued at $195 million, ...

Young patients with colorectal cancer often had more aggressive forms of the disease, like signet-ring cell and mucinous ...

Patients with appendiceal adenocarcinoma face increased risk of secondary cancers, including colorectal, within 10 years, per ...

Although ctDNA positivity generally meant worse disease-free survival in stage 3 resected colon cancer, patients with ctDNA ...

Inhibrx (INBX) announced preliminary efficacy and safety data from the Phase 1 trial of ozekibart in combination with Folfiri for the treatment ...

Conclusions: Even in cases of colorectal carcinoma with deep submucosal invasion, the risk of lymph node metastasis is minimal under certain conditions. Thus, even for such cases, endoscopic ...

By studying biomarkers known to be involved in gastrointestinal cancers, researchers have developed a biomarker algorithm that, when combined with a noninvasive method to collect esophageal cells for ...